Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology

2026-02-08 - 10:38

SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company (“Lilly”) to advance novel medicines